|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||18.86|
|Forward Dividend & Yield||0.73 (1.89%)|
|1y Target Est||N/A|
- Midazolam Nasal Spray has been granted orphan drug designation by the United States Food and Drug Administration (US FDA) for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. BRUSSELS and ATLANTA, Aug. 13, 2018 /PRNewswire/ -- UCB today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for midazolam nasal spray*, an investigational product for the acute treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g.
SAN FRANCISCO, Aug. 8, 2018 /PRNewswire/ -- MyHealthTeams and UCB today introduce the Spondyloarthritis Resource Center within MySpondylitisTeam, the social network for people living with spondyloarthritis (SpA). Spondyloarthritis is an inflammatory disease that affects the spine and can affect the joints of the arms and the legs. In some people, spondyloarthritis can also affect the skin, intestines and eyes.
With a market capitalization of €13.95b, UCB SA (EBR:UCB) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big stocks areRead More...
THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture. "A fracture due to osteoporosis can be a life-altering event, and EVENITY has the potential to reduce fracture risk in patients at high risk due to a prior fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
The AIM Movement provides support, information and a place to share stories about motherhood in women with chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and Crohn's disease (CD). ATLANTA, July 11, 2018 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the Autoimmune Motherhood (AIM) Movement to support women living with chronic inflammatory or autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and Crohn's disease (CD), as they attempt to balance disease management with concerns and considerations related to family planning, pregnancy and breastfeeding.
NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. Belgium-based global bio-pharmaceutical company UCB today announced it has received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA), creating a pathway to make the company's 24-hour continuous delivery transdermal rotigotine patch NEUPRO® available to patients in China.
UCB SA (ENXTBR:UCB) is trading with a trailing P/E of 16.5x, which is lower than the industry average of 23.4x. Although some investors may jump to the conclusion that thisRead More...
BRUSSELS , May 16, 2018 /PRNewswire/ -- Positive top line results from Phase 3 C-AXSPAND study underscore the potential of CIMZIA ® (certolizumab pegol) for non-radiographic axial spondyloarthritis (nr-axSpA), ...
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company's newest anti-epileptic drug (AED) BRIVIACT® (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial onset (focal) seizures in patients age four years and older. This approval provides clinicians with the convenient option to prescribe BRIVIACT to their pediatric patients as a tablet or oral solution, providing flexible administration options which are important considerations when treating children.
UCB SA (ENXTBR:UCB) outperformed the Pharmaceuticals industry on the basis of its ROE – producing a higher 13.42% relative to the peer average of 11.62% over the past 12 months.Read More...
Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018. Nasal administration could provide significant value to patients who currently have limited treatment options.
Investors pursuing a solid, dependable stock investment can often be led to UCB SA (ENXTBR:UCB), a large-cap worth €12.49B. One reason being its ‘too big to fail’ aura which givesRead More...
UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. Element Genomics' proven technologies and expertise will enhance UCB's scientific research platform enabling the company to continue to enrich its pipeline, in particular strengthening target discovery and characterization in disease relevant systems.
When UCB SA’s (ENXTBR:UCB) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I used wereRead More...
UCB SA (ENXTBR:UCB) received a lot of attention from a substantial price movement on the ENXTBR in the over the last few months, increasing to €71.12 at one point, andRead More...
BRUSSELS , March 22, 2018 /PRNewswire/ -- U.S. Food and Drug Administration (FDA) approves label change for UCB's CIMZIA ® (certolizumab pegol) Data added to the label includes first-of-their-kind pharmacokinetic ...
"UCB is thrilled to participate in the important scientific exchange at AAD this week and to translate our learnings into improved patient care. "As our research at AAD shows, UCB is executing on its Patient Value Strategy to connect the unmet needs of patients with innovative science.
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 7, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. If approved in Europe, EVENITY will be a novel osteoporosis treatment that increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture.
BRUSSELS , Nov. 6, 2017 /PRNewswire/ -- Key data focus on inflammatory and osteoporosis in patient populations with unmet needs including women of childbearing age and others: The results from the first-of-its-kind ...
ATLANTA and BRUSSELS , Nov. 6, 2017 /PRNewswire/ -- VIMPAT® (lacosamide) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset ...
Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes
-- New indication comes just 18 months after launch of BRIVIACT® in the U.S. This is a new indication for BRIVIACT, which is already approved in the U.S. as adjunctive treatment for POS in patients in this age group.
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* (romosozumab) followed by alendronate was superior in reducing new vertebral, clinical, non-vertebral and hip fracture risk in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone. Overall adverse events and serious adverse events were generally similar between the treatment groups with the exception of the previously reported imbalance in positively adjudicated cardiovascular serious adverse events.